AstraZeneca reported 9M and Q3 2026 results on 30 October 2026 with third-quarter Core earnings per share of $2.79, up 17% on an actual basis and 19% at constant exchange rates, on total revenue of $16,209m, up 7%. Consensus had sat at roughly $2.60 a share — the figure is quoted as $2.59 by some providers and about $2.60 by others — so the beat was in the order of 7% to 8%. Revenue also came in ahead of a consensus near $15.99bn. The shares closed around 7% higher on the day, finishing at roughly 13,960p against a previous close of 13,052p.
For anyone running an AstraZeneca stock analysis off this print, the number that matters is not the beat itself but what management did next: nothing. Full-year 2026 guidance was reconfirmed, not raised — mid-to-high single-digit total revenue growth and low double-digit Core EPS growth, both at constant currency. That leaves the central question of this quarter in plain view. Nine-month Core EPS of $8.00 is up 14%, the third quarter alone grew 19% at constant rates, and the full-year target is low double digits. Those three figures cannot all be the run rate. One of them has to give, and which one it is decides whether the 7% re-rating was the market recognising durable earnings power or capitalising a single favourable quarter.
What actually happened
The quarter was driven by oncology, as the last several have been. Nine-month oncology revenue rose 16% to $21.9bn, with the company naming Tagrisso, Imfinzi, Calquence and Enhertu as the principal contributors. Third-quarter oncology growth was reported at 17% across two separate write-ups of the results. Alongside the commercial numbers, AstraZeneca pointed to twelve positive Phase III programme readouts in the year to date — a pipeline statistic rather than a revenue one, but the input that underwrites the company's stated ambition of $80bn of revenue by 2030.
Two further details matter more than they first appear. The first is currency. Revenue grew 7% on both an actual and a constant-currency basis, so translation was broadly neutral at the top line. Core EPS, by contrast, grew 17% actual against 19% at constant rates, meaning currency cost roughly two percentage points of earnings growth in the quarter. Anyone comparing the headline EPS growth rate against a constant-currency guidance range is comparing two different things.
The second is the gap between the two EPS figures the company published. Core EPS was $2.79. Reported EPS — the GAAP figure — was $2.02, up 23% on an actual basis and 26% at constant rates. That is a $0.77 wedge between the adjusted and the statutory number, and it is wider this quarter than usual because of a newly disclosed restructuring programme.
That programme is called Reshaping for Sustainable Growth. The figures attached to it were reported inconsistently in the first hours after the release, and the reason is instructive: there are two different numbers and they measure opposite things. The programme is expected to incur up to $2.0bn in one-time restructuring costs and to deliver $1.5bn in annualised pre-tax run-rate benefits. Related activities are expected to complete by the end of 2029, with the savings reinvested principally in the pipeline. A $2bn cost and a $1.5bn annual saving are not a contradiction; they are the two sides of the same programme, and conflating them produces a meaningfully wrong picture of either the cash cost or the margin benefit.
Why the market reacted the way it did
A 7% move in a company of AstraZeneca's size is a re-rating, not a trading reaction. On the day it was enough to make the stock the dominant positive contributor to a higher FTSE 100 close, with the pharmaceutical sector leading London's gains.
The reaction is best understood as the market revising its view of earnings quality rather than earnings level. A 7% to 8% EPS beat on its own does not move a mega-cap pharmaceutical 7%, because a single quarter's beat can come from phasing, inventory movements, or a soft comparative. What moves the share price is evidence that the growth engine is broader and more repeatable than assumed. Oncology growing 16% over nine months across four separate named franchises is a different proposition from one blockbuster carrying the quarter, because franchise breadth is what makes a growth rate survive a single patent event or a single competitive entry.
There is also a reflexive element in the guidance decision. Management reconfirming rather than raising full-year guidance after a 19% constant-currency quarter is either conservatism or a signal. The market, on the day, read it as the former. That reading is defensible — companies rarely raise guidance in the third quarter when the fourth-quarter comparative is tougher — but it is a reading, not a fact, and it is the single most testable assumption in the current price.
The Openbook read
Taking the five factors in turn, this print moves three of them and leaves two broadly where they were.
- Growth improves, but at the nine-month level rather than the third-quarter level. The honest growth input here is 14% constant-currency Core EPS growth across nine months, not the 19% the quarter delivered in isolation. Arithmetic forces the point: to land the full year in the low double digits off 14% nine-month growth, fourth-quarter Core EPS growth must come in materially below the third quarter's. Whether that is prudence or guidance is unresolved, and a growth score built on 19% is a score built on the most favourable quarter of the year.
- Profitability strengthens on a core basis and weakens on a reported one, which is exactly why the basis has to be stated. Core EPS growth outpacing revenue growth — 19% against 7% at constant rates — is operating leverage. But the reported figure carries the restructuring charge, and the up-to-$2.0bn cost lands before the $1.5bn of annual benefit does. A profitability read that uses only the core number is flattering the next three years and ignoring the cash that pays for them.
- Momentum is the factor that moves most. A 7% single-session gain on heavy volume, in a sector leading the index, is a genuine momentum improvement, and it came with a fundamental rather than a speculative trigger.
- Solvency is substantially unchanged by this release. The quarter did not introduce new balance-sheet information of consequence, and the restructuring cash cost is spread to the end of 2029 rather than concentrated. This is a neutral, and it should be scored as one rather than as an implied positive borrowed from the earnings beat.
- Reward/Risk is the factor that deteriorates on good news, and this is the part most easily missed. The beat was roughly 7% to 8%; the share price moved roughly 7% in a day. In other words the market has now priced close to the entire surprise, and it has done so against guidance that was not raised. The asymmetry that existed before the print — a company compounding core earnings in the mid-teens at a valuation set before the oncology breadth was visible — is narrower afterwards. Nothing about the business got worse; the price simply caught up with it, and the remaining upside now depends on the fourth quarter validating the third rather than on the market re-rating the same information twice.
The composite read is a company whose Growth and Profitability inputs are genuinely better than they were a week ago, offset by a Reward/Risk input that is worse because the shares already reflect it. That is a different conclusion from "strong results, strong stock", and it is the distinction the five-factor frame exists to force. Current factor scores are on the AstraZeneca factor page.
The read-across
The immediate read-across is to the rest of UK-listed pharmaceuticals. GSK is the obvious comparator, and the relevant point is not that a rising tide lifts both — it is that AstraZeneca's quarter was oncology-led and franchise-broad, which is a specific attribute rather than a sector condition. A read-across that assumes GSK benefits simply because both are large UK pharmaceutical companies is the kind of sector-level reasoning that this print argues against.
For the index, the effect is mechanical and significant. AstraZeneca is among the largest constituents of the FTSE 100, and a 7% move in it is worth more to the index than a 7% move in most of the companies below it. Investors holding UK large-cap index exposure took a meaningful single-stock gain on 30 October whether they intended that concentration or not, and the concentration cuts both ways on the next print. The wider implication for globally listed oncology peers — Merck and Novartis among them — is that competitive intensity in the categories AstraZeneca cited is rising rather than falling, which is a cost pressure on everyone in the flow. Comparable large-cap pharmaceutical names can be screened side by side on the Openbook screener.
What to watch next
Four specific triggers sit between now and a resolution of the question this print left open.
- Full-year 2026 results, due in February 2027. This is the decisive one. It reveals the fourth-quarter Core EPS growth rate, and therefore whether the 19% third quarter or the 14% nine-month figure was the better guide. It is also the first natural opportunity for management to move the guidance range rather than reconfirm it.
- The first restructuring charges flowing through reported earnings. Watch the size and phasing of the up-to-$2.0bn cost, and whether the $1.5bn annualised benefit is reiterated with a date attached as the programme progresses toward its end-2029 completion.
- Phase III readouts through 2027. Twelve positive readouts year to date is the pipeline statistic underwriting the $80bn 2030 ambition, and the 2027 readout schedule is where that ambition is either corroborated or quietly deferred.
- Currency. With roughly two percentage points of third-quarter EPS growth lost to translation, the gap between actual and constant-currency reporting is wide enough to matter. Any guidance commentary should be read at constant currency and compared with constant-currency actuals, not with the headline.
The event was a clear beat. The open question is whether the quarter was the run rate, and management declined to say so. That is the whole analysis.
Discussion
Log in to join the discussion